EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The role of serum tryptase in COVID-19 pathogenesis and its value as a prognostic marker: a single-center prospective cohort study

Alan Majeranowski, Damian Palus, Michał Hoffmann, Zbigniew Heleniak, Tomasz Stefaniak, Krzysztof Kuziemski

Acta Biochimica Polonica · 2026

DOI: 10.3389/abp.2026.15936 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Acta Biochimica Polonica, 2026. Verfasst von Alan Majeranowski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Intercollegiate Faculty of Biotechnology, The University of Gdańsk, Gdańsk, Poland. Hauptthemen laut MEDLINE: Tryptases, COVID-19. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dysregulated inflammation is central to COVID-19 pathogenesis. Mast cells (MCs) and their protease tryptase are implicated in tissue injury and vascular dysfunction, but the prognostic value of circulating tryptase in COVID-19 remains uncertain.

Methods

We conducted a prospective cohort study including 82 patients with laboratory-confirmed COVID-19 admitted between January and March 2021. On admission, serum tryptase, C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), and lymphocyte counts were measured. The objective of this study was to assess whether serum tryptase levels measured upon hospital admission are associated with COVID-19 severity and in-hospital mortality. Statistical analyses comprised t-tests, Mann–Whitney U tests, χ 2 tests, receiver operating characteristic (ROC) curve analysis, and logistic regression.

Results

Serum tryptase levels at admission did not differ significantly between patients requiring oxygen and those who did not (mean 5.45 vs. 4.97 μg/L; p = 0.2906) or between survivors and non-survivors (mean 5.24 vs. 5.60 μg/L; p = 0.6486). ROC analysis confirmed limited prognostic performance for tryptase regarding oxygen requirement (AUC = 0.580; p = 0.2972) and mortality (AUC = 0.538; p = 0.6103). By contrast, CRP, PCT, and LDH correlated strongly with disease severity. Elevated PCT (p = 0.0016) and LDH (p = 0.0360) were significantly associated with mortality. Logistic regression showed no independent association between tryptase and adverse outcomes.

Conclusion

In this prospective cohort, serum tryptase measured at admission was not associated with COVID-19 severity or mortality, suggesting limited utility as a prognostic biomarker. Established markers, particularly PCT and LDH, outperformed tryptase in predicting adverse clinical outcomes. The negative findings are clinically relevant as they demonstrate that tryptase does not contribute to prognostic risk stratification in COVID-19, and its measurement does not provide added value beyond standard inflammatory biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TryptasesCOVID-19HumansFemaleMaleProspective StudiesBiomarkersPrognosisMiddle AgedAgedC-Reactive ProteinSARS-CoV-2Hospital MortalityROC CurveSeverity of Illness IndexL-Lactate DehydrogenaseProcalcitonin

Stichwörter der Autor:innen

COVID-19inflammationmast cellsprognostic biomarkertryptase

Substanzen

TryptasesBiomarkersC-Reactive ProteinL-Lactate DehydrogenaseProcalcitonin

Autor:innen und Institutionen

  • Intercollegiate Faculty of Biotechnology, The University of Gdańsk, Gdańsk, Poland.
  • Department of Hypertension and Diabetology, Medical University in Gdańsk, Medical Faculty, Gdańsk, Poland.
  • University Clinical Centere, Medical University of Gdańsk, Gdańsk, Poland.
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University in Gdańsk, Medical Faculty, Gdańsk, Poland.
  • Department of Quality in Healthcare, Medical University in Gdańsk, Medical Faculty, Gdańsk, Poland.
  • Department of Surgical Oncology, Transplant Surgery and General Surgery, Medical University in Gdańsk, Medical Faculty, Gdańsk, Poland.

Zitieren

APA

Majeranowski, A., Palus, D., Hoffmann, M., Heleniak, Z., Stefaniak, T., & Kuziemski, K. (2026). The role of serum tryptase in COVID-19 pathogenesis and its value as a prognostic marker: a single-center prospective cohort study. Acta Biochimica Polonica. https://doi.org/10.3389/abp.2026.15936

Vancouver

Majeranowski A, Palus D, Hoffmann M, Heleniak Z, Stefaniak T, Kuziemski K. The role of serum tryptase in COVID-19 pathogenesis and its value as a prognostic marker: a single-center prospective cohort study. Acta Biochimica Polonica. 2026. doi:10.3389/abp.2026.15936

BibTeX
@article{Majeranowski2026,
  author = {Majeranowski, Alan and Palus, Damian and Hoffmann, Michał and Heleniak, Zbigniew and Stefaniak, Tomasz and Kuziemski, Krzysztof},
  title = {The role of serum tryptase in COVID-19 pathogenesis and its value as a prognostic marker: a single-center prospective cohort study},
  journal = {Acta Biochimica Polonica},
  year = {2026},
  doi = {10.3389/abp.2026.15936}
}
Kostenlos starten →